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Abstract
DC-SIGN (Dendritic cell-specific ICAM-3-grabbing non-integrin) is a Ca2+-dependent
transmembrane lectin that binds a large variety of pathogens and facilitates their uptake for
subsequent antigen presentation. This receptor is present in cell surface microdomains, but factors
involved in microdomain formation and their exceptional stability are not clear. To determine
which domain/motif of DC-SIGN facilitates its presence in microdomains, we studied mutations at
key locations including truncation of the cytoplasmic tail, and ectodomain mutations that resulted
in removal of the N-linked glycosylation site, the tandem repeats and the carbohydrate recognition
domain (CRD) as well as modification of the calcium sites in the CRD required for carbohydrate
binding. Confocal imaging and FRAP measurements showed that the cytoplasmic domain and N-
linked glycosylation site do not affect the ability of DC-SIGN to form stable microdomains.
However, truncation of the CRD results in complete loss of visible microdomains and subsequent
lateral diffusion of the mutants. Apart from cell adhesions, membrane domains are thought to be
localized primarily via the cytoskeleton. By contrast, we propose that interactions between the
CRD of DC-SIGN and the extracellular matrix and/or cis interactions with transmembrane
scaffolding protein(s) play an essential role in organizing these microdomains.
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Introduction
Dendritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN) is a pattern recognition
receptor which is expressed by monocyte-derived dendritic cells (DCs). It binds to mannose
and fucose structures on the surface of a broad range of pathogens, including viruses,
bacteria and parasites and plays a crucial role in stimulation of diverse immune responses
(1). This receptor is of fundamental importance for understanding the molecular mechanism
underlying pathogen recognition by DCs. This lectin captures pathogens through
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interactions between its carbohydrate recognition domain (CRD) and carbohydrates on the
surface of pathogens. The monomeric CRD exhibits low binding affinity to high mannose
carbohydrates, while tetramerization of DC-SIGN, facilitated by the tandem repeats in the
extracellular region, greatly enhances DC-SIGN’s binding affinity (2). Moreover, DC-SIGN
forms clusters or microdomains on the DC plasma membrane (3–5) that act as docking sites
for various pathogens. Clustering of DC-SIGN probably not only increases its avidity to
carbohydrate ligands, but also modulates its specificity by favoring carbohydrates with a
certain density and spacing (6). We reported that cell lines ectopically expressing DC-SIGN
also form similar, discrete surface microdomains that range in size from the diffraction limit
to over 1 µm in diameter (5). These microdomains are extremely stable on the cell
membrane in terms of the lack of lateral movement of DC-SIGN within the microdomains
as well as the lack of exchange of the lectin with any pool in the surrounding membrane,
although occasionally the microdomains will exhibit rapid retrograde transport prior to
internalization (5, 7). Moreover, microdomain formation and stability do not appear to
require the cytoplasmic domain of DC-SIGN (7).
At this juncture, the molecular origins of the formation and unexpected stability of DC-
SIGN microdomains remain a mystery. Because DC-SIGN forms microdomains when
ectopically expressed in a variety of cells (5), a mutational strategy offers one approach to
unraveling this mystery. We generated a collection of mutants in which the cytoplasmic
domain was deleted, the N-linked glycosylation site was not operative, the tandem repeats
were deleted, or the CRD was deleted. We then evaluated domain formation visually with
fluorescence microscopy and measured the size of the microdomains, if they existed; the
stability of the microdomains was evaluated by fluorescence recovery after photobleaching
(FRAP) since we knew that wild-type (wt) DC-SIGN microdomains are extraordinarily
stable, exhibiting almost no recovery (5, 7). Our results indicate that the tandem repeats and
CRD play crucial roles in DC-SIGN microdomain formation and stability, the latter either
by directly interacting with extracellular matrix components and/or via cis interactions with
a transmembrane adaptor protein(s). This result has significance beyond DC biology since
there is little precedence for extracellular stabilization of membrane domains apart from




Different regions of DC-SIGN were mutated to investigate which domain/motif(s) of DC-
SIGN facilitate microdomain formation and stability. Four types of mutations were
produced (Figure 1A): truncation of the cytoplasmic region (the first 37 amino acids at the
N-terminus were removed, denoted as DC-SIGN-Δ37); a point mutation of the N-linked
glycosylation site (denoted as DC-SIGN-N80Q) that prevents glycosylation at this site;
deletion of the seven and one half tandem repeats in the extracellular region (denoted as DC-
SIGN-ΔRepeats); and truncation of the CRD (denoted as DC-SIGN-ΔCRD). An AU1
antigenic tag was introduced at the C-terminus of the ΔCRD mutation, so that the truncated
receptor could be directly detected by a fluorescent dye - conjugated monoclonal antibody
(mAb). In addition, EGFP conjugated forms of wt and these mutations were generated.
Figure 1B shows the Western blots obtained from cells expressing wt DC-SIGN or its
mutants. Figures 2, 3, 4, 5, and 6 present the images, FRAP and microdomain sizing results
characterizing these mutant DC-SIGN molecules; the results are summarized in Table 1.
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Neither the cytoplasmic tail of DC-SIGN nor its N-linked glycosylation site is required for
stable cell surface microdomains
We previously found that microdomains of DC-SIGN on cell surfaces are extremely stable
in terms of location and diffusion of the receptor within the microdomain, as well as
exchange between the microdomain and surround (5, 7). One possibility is that the
cytoplasmic tail of DC-SIGN may directly associate with cytoskeletal structures, such as
actin filaments, that stabilize the microdomains on the surface and immobilize DC-SIGN
within the microdomains. If this hypothesis is correct, truncation of the cytoplasmic region
would eliminate such interactions and release immobile DC-SIGN. However, two
cytoplasmic truncation mutants, DC-SIGN-Δ20 and DC-SIGN-Δ35, still form stable,
discrete microdomains on cell membranes (7). To confirm and extend these earlier
measurements, we made the DC-SIGN-Δ37 construct (Figure 1A), which further removed
residue Cys37, the single cysteine that locates outside the CRD. As shown in Figure 2 C and
D, DC-SIGN-Δ37 (mAb-labeled) and GFP-DC-SIGN-Δ37 still formed discrete
microdomains on cell membranes, indicating that residue Cys37 is not directly involved in
the membrane microdomain formation.
Next, we carried out FRAP measurements on cells expressing DC-SIGN-Δ37 (visualized
with a dye-conjugated mAb; i.e., AlexaFluor 488 conjugated 120507 mAb) or GFP-DC-
SIGN-Δ37 to examine whether these mutants could diffuse within the microdomain and
exchange with the surround. As shown in Figure 3 C and D, little recovery was observed
after photobleaching, indicating that the microdomains formed by DC-SIGN-Δ37 or GFP-
DC-SIGN-Δ37 are stable and do not exchange appreciably with surrounding molecules of
the same type, similar to those formed by wt DC-SIGN (Figure 3 A and B) (5, 7). Therefore,
truncation of the cytoplasmic region of DC-SIGN does not significantly affect either
microdomain formation or stability.
One potential function of residue Cys37, in the cytoplasmic tail of DC-SIGN near the inner
leaflet of the plasma membrane, is that it may be a palmitoylation site, similar to the
cysteine residues in the juxtamembrane region of β1-adrenergic receptors (8). Like the
palmitoylation of the cysteine residue in the plasma membrane targeting sequence of the
retinitis pigmentosa protein RP2 (9), palmitoylation of the cysteine residue in the
juxtamembrane region may help to stabilize the receptor in the plasma membrane, and may
also function in concentrating the receptors in certain membrane regions that are rich in
saturated lipids (10). Indeed, we observed a colocalization of wt DC-SIGN with a membrane
fluorescent protein probe, PMT-mRFP (plasma membrane target mRFP, which contains a
myristoylation site and a potential palmitoylation site (9, 11)), when coexpressing wt DC-
SIGN and PMT-mRFP in NIH3T3 cells (Figure S1, Supporting information), consistent
with previous reports of ‘raft’ localization of DC-SIGN (3, 12). However, since DC-SIGN-
Δ20, DC-SIGN-Δ35 and DC-SIGN-Δ37 are all able to form stable surface microdomains, it
is unlikely that the microdomains are maintained by interactions involving potential
palmitoylation of DC-SIGN and inner leaflet lipids.
The N-linked consensus sequence is Asn-X-Ser/Thr, in which X can be any amino acid
except proline. DC-SIGN contains a potential N-linked glycosylation site, residues Asn80-
Leu81-Thr82 (13). Extracellular secreted galectins bind to exposed sugar residues forming
putative galectin-glycoprotein lattices on the cell surface (14). Thus, DC-SIGN could be
cross-linked by galectins through the glycosylated Asn80, which might be a mechanism for
DC-SIGN microdomain formation. To test this hypothesis, we switched residue Asn80 to a
Gln by site-directed mutagenesis. As shown in Figure 2 E and F, both DC-SIGN-N80Q and
GFP-DC-SIGN-N80Q still form distinct surface microdomains and little recovery was
observed after photobleaching such microdomains (Figure 3 E and F, respectively).
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Therefore, our results imply that N-glycosylation on residue Asn80 is not a primary factor
involved in DC-SIGN microdomain formation or stability.
Note that the total numbers of microdomains in Figures 2 B, D, and F (the GFP-containing
constructs) are less than the numbers of microdomains formed by the corresponding non-
GFP containing constructs. This result may be caused by the proximity of GFP to the inner
leaflet, which could affect a step and/or steps during initial synthesis, plasma membrane
delivery, and/or microdomain formation. However, the average number of microdomains on
cells expressing GFP-DC-SIGN-N80Q is approximately equivalent to cells expressing GFP-
DC-SIGN (Table 1).
To examine whether there is a size difference between the microdomains formed by wt DC-
SIGN and the microdomains formed by the various mutants, we measured the size
distributions of these microdomains. Figure 4 A–F gives the size distribution of
microdomains formed by each DC-SIGN construct. In general, the microdomains formed by
wt DC-SIGN are smaller and more uniform in dimension, while the microdomains formed
by the DC-SIGN-Δ37 and N80Q mutations are larger and exhibit a larger size range (Figure
4 G and Table 1). This result suggests that the cytoplasmic tail and the glycosylation site
play a role in fine-tuning the microdomain structure. Indeed, as reported by Serrano-Gómez
et al., the glycosylation site mutation (N80Q) resulted in an increased proportion of high
order oligomers compared to wt DC-SIGN (15). On the other hand, the three EGFP fusions
all exhibit a larger microdomain size compared to the microdomains formed by their
corresponding non-fluorescent mutant proteins; it is possible that the cytoplasmic tail might
also negatively affect oligomer formation and that an EGFP tagged to the terminus of the
cytoplasmic tail may reduce such an effect. Nonetheless, as both the cytoplasmic tail
truncation and glycosylation site mutation of DC-SIGN form stable, discrete microdomains,
we conclude that the neither the cytoplasmic tail nor N-linked glycosylation provides the
major driving force for surface microdomain formation.
Deletion of the tandem repeats results in a combination of lateral diffusion of DC-SIGN and
some microdomain formation on cell surfaces
In contrast to the cytoplasmic truncation and N-linked glycosylation site mutation, deletion
of the tandem repeats of DC-SIGN results in loss of stable microdomains. Figure 5 A shows
that diffuse membrane fluorescence was observed on cells expressing either the GFP-DC-
SIGN-Δrepeats (A-1) or the DC-SIGN-Δrepeats labeled with 120507 mAbs conjugated to
AlexaFluor 488 (A-2). FRAP measurements on these cells show that after deletion of the
tandem repeats the majority of the receptors are mobile on the membrane (Figure 5 C and
D). The mobile fractions, P∞, for GFP-DC-SIGN-Δrepeats and mAb labeled DC-SIGN-
Δrepeats are 78 ± 5% (±SEM, N=13) and 67 ± 10% (±SEM, N=10), respectively. The
corresponding diffusion coefficients, D, for GFP-DC-SIGN-Δrepeats and DC-SIGN-
Δrepeats labeled by Alexa488-conjugated mAb are 0.12 ± 0.02 µm2/s (±SEM, N=13) and
0.08 ± 0.03 µm2/s (±SEM, N=10), respectively. A fraction of cells expressing either GFP-
DC-SIGN-Δrepeats or DC-SIGN-Δrepeats (mAb-labeled), particularly at high expression
levels, showed some punctate labeling together with diffuse membrane fluorescence. Figure
5 B gives an example of a cell expressing GFP-DC-SIGN-Δrepeats, which showed bright
microdomain-like spots (Figure 5 B-1; red arrow) as well as diffuse membrane fluorescence
(Figure 5 B-1; yellow arrow). Such ‘microdomains’ differ markedly from the stable domains
formed by wt DC-SIGN because 1) the ‘domains’ are dynamic and can often move from one
position to other positions on the membrane, as observed by time-lapse confocal imaging
(data not shown); and 2) DC-SIGN within these ‘domains’ is able to exchange with DC-
SIGN in the surrounding membrane, as shown by the recovery after photobleaching (Figure
5 E and F). The recovery curves of these ‘dynamic microdomains’ are often non-monotonic,
which might be due to membrane fluctuation or slight domain movement during the
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recovery phase. In addition, the recovery rate is slower compared to that in the surrounding
membrane, suggesting that transient binding to anchoring structures within the microdomain
and/or a partially permeable barrier surrounding the microdomain may be occurring (16,
17).
The observation of diffuse membrane fluorescence and ‘dynamic microdomains’ on cells
expressing the tandem repeats deletion mutation is different from the observation on cells
expressing the CRD truncation mutants, which only show homogenous, diffuse membrane
fluorescence, as we discuss in the next section. One possibility is that after removal of the
tandem repeats, DC-SIGN partially retains its biological function; i.e., the CRD could still
bind to ligands that now weakly promote the formation of much less stable microdomains.
Truncation of the CRD results in complete loss of visible microdomains on cell surfaces
Removal of the CRD of DC-SIGN results in a complete loss of visible microdomains on the
cell surface. Figure 6 A shows that cells expressing GFP-DC-SIGN-ΔCRD (Figure 6 A-1
and A-3) and cells expressing DC-SIGN-ΔCRD labeled by FITC-conjugated mAb against
the AU1 tag (Figure 6 A-2 and A-4) exhibit diffuse membrane fluorescence, but no distinct
surface microdomains. Furthermore, recovery was observed after photobleaching a circular
membrane area (Figure 6 B and C), indicating that CRD truncation mutants are laterally
mobile in the plasma membrane. The average mobile percentage P∞ for GFP-DC-SIGN-
ΔCRD is 95 ± 4 % (±SEM, N=15), and for DC-SIGN-ΔCRD labeled by FITC-conjugated
mAb the P∞ value is 73 ± 7% (±SEM, N=11). The diffusion coefficients, D, for GFP-DC-
SIGN-ΔCRD and DC-SIGN-ΔCRD labeled by FITC-conjugated mAb are 0.18 ± 0.02 µm2/
s (±SEM, N=15) and 0.02 ± 0.01µm2/s (±SEM, N=11), respectively. Nonetheless, both the
mAb-labeled and the GFP-fused CRD truncation mutants showed diffuse and homogenous
membrane fluorescence, indicating that DC-SIGN loses both its ability to form
microdomains as well as its immobilization on the membrane without the CRD. This
behavior was independent of expression level (not shown). These experiments form, in a
sense, a positive control for the cytoplasmic truncation and N-linked glycosylation site
mutants in which microdomains were formed and very little fluorescence recovery after
photobleaching was observed.
Lastly, preliminary data show that mutating one of the seven residues involved in calcium
coordination that are key to saccharide binding in the CRD also shows no evidence for
microdomains and that the mutant exhibits nearly complete recovery (Figure S2, Supporting
information); this result further implicates saccharide binding in the CRD as the primary
source of DC-SIGN stabilization in microdomains.
DISCUSSION
Because the molecular origins of the formation and unexpected stability of DC-SIGN
microdomains were unknown, we pursued a mutational approach to investigate these
intriguing issues. These mutations were aimed to disrupt the cytoplasmic and extracellular
regions of DC-SIGN. This strategy is at least partially justified by the observation that DC-
SIGN becomes laterally mobile in giant plasma membrane vesicles formed from cells
expressing the receptor as judged by its collection at the interface between two closely
apposed vesicles (Levental I., Liu P., Thompson N. L., Simons K. and Jacobson K.,
unpublished results); such vesicles would be expected to have significantly depleted
associated cytoskeletal and pericellular matrix structures (18, 19). Moreover, ectopically
expressed DC-SIGN forms domains that are similar to those found in DCs (5, 7). It should
be noted that our analysis was performed using widefield microscopy methods. However, as
shown by super-resolution Blink Microscopy and electron microscopy, domains that appear
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contiguous in widefield microscopy are most likely composed of arrays of nanodomains of
dimensions < 100 nm (4, Itano et al., unpublished).
We extended our previous finding (7) that DC-SIGN cell surface microdomain formation
does not require its cytoplasmic tail. The conventional notion would be that the cytoplasmic
tail of DC-SIGN could associate with cytoskeleton structures proximate to the membrane
and that this would confer the extreme stability of wt DC-SIGN microdomains. Indeed,
Gringhuis et al. reported that the cytoplasmic domain of DC-SIGN constitutively associates
with scaffold proteins LSP1 (Leukocyte-specific protein 1), KSR1 (kinase suppressor of
Ras1) and CNK (connector enhancer of KSR); moreover, LSP1 is an actin-binding protein
(20). Therefore one might expect that DC-SIGN could be immobilized through a linkage
from its cytoplasmic tail to the membrane apposed cytoskeleton via scaffold proteins.
However, the three cytoplasmic mutants (DC-SIGN-Δ20, DC-SIGN-Δ35 and DC-SIGN-
Δ37) tested in this and our previous work (7) all form stable microdomains in the plasma
membrane, indicating that direct association between the cytoplasmic domain of DC-SIGN
and the membrane-apposed cytoskeleton is not the major initial driving force for membrane
microdomain formation and stability. This conclusion does not preclude cis associations
with other transmembrane proteins that are themselves linked to the membrane apposed
cytoskeleton (Figure 7), although administration of two different actin cytoskeletal
disrupting drugs, cytochalasin D and latrunculin, did not affect microdomain formation
(Supplemental Figure S3). Whether or not the cytoskeleton is indirectly involved in
microdomain stability, the cytoplasmic tail is certainly involved via adaptors and scaffolding
proteins in various downstream signaling networks in response to pathogen binding (20, 21).
The N-linked glycosylation site is not required for microdomain formation and stability.
Using biochemical assays, the N80Q mutation has been reported to form higher order
oligomers other than monomers or tetramers (15) which may contribute to the fact that the
N80Q mutant forms larger sized microdomains. Moreover, putative galectin-mediated lattice
formation (14) employing this glycosylation site does not appear to occur.
In terms of proposing a mechanism for the formation and unusual stability of DC-SIGN
microdomains, the most intriguing observations are that the tandem repeats deletion and
CRD truncation resulted in the loss of stable microdomains. The tandem repeats region is
proposed to facilitate tetramerization of DC-SIGN by forming coiled-coil α-helices (13),
and biochemical assays have shown that after deletion of the tandem repeats DC-SIGN is
not able to tetramerize, and instead exists mainly as monomers (15, 22). It has also been
suggested that the tandem repeats and the CRD fold independently, and that the CRD is
flexibly linked to the tandem repeats (22). Therefore, it is feasible that after removal of
either the tandem repeats or the CRD, the remaining sequence could still fold properly.
We observed a complete loss of microdomain formation in cells expressing the CRD
truncation mutants, and both DC-SIGN-ΔCRD (mAb-labeled) and GFP-DC-SIGN-ΔCRD
are able to laterally diffuse on the plasma membrane. This observation indicates that DC-
SIGN with the tandem repeats region alone, but lacking the CRD, is not able to form stable
microdomains although it could still tetramerize as reported by Yu et al. (23). By contrast,
after deleting the tandem repeats, the receptor was still able to form some dynamic
microdomains on cell surfaces especially at high expression levels. This observation
indicates that the CRD has the capability to promote clustering although such clusters lack
the extreme stability of wt DC-SIGN microdomains. These results suggest the hypothesis
that the CRD plays a major role in microdomain formation and the tandem repeats co-
operate and stabilize the microdomains.
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Indeed, our results lead to the proposal of a model for the origin of DC-SIGN microdomain
stability. Microdomain stability may be primarily facilitated by the CRD of DC-SIGN
directly binding to polysaccharides (e.g., glycosaminoglycans or glycosyl moieties of
extracellular matrix (ECM) proteins) in the ECM (Figure 7 A), or, by DC-SIGN directly
binding to transmembrane proteoglycans that link to the ECM (Figure 7 B). It is also
possible that glycosylated transmembrane adaptor proteins (TRAPs) (24), that are directly or
indirectly linked to the membrane apposed cytoskeleton and have cis interactions with DC-
SIGN, serve to stabilize these microdomains (Figure 7 C). For example, the CRD of DC-
SIGN could recognize transmembrane proteoglycans (25) that are linked to the cytoskeleton
thus serving to stabilize microdomains. Such proteins could also serve as pathogen co-
receptors enabling differentiation of downstream pathways in response to the variety of
pathogens that DC-SIGN binds (20, 21, 26). Although not depicted, it is also possible that
secreted galectins (14) could mediate formation and stabilization of microdomains via
binding smaller saccharide ligands bound to the CRD and glycosyl moieties of ECM
components and/or transmembrane proteoglycans and TRAPs.
The tandem repeats region in this hypothesis would play two important roles: first, it is
involved in oligomerizing/tetramerizing the receptors (15, 23) which acts to increase the
avidity by providing four CRDs in close proximity; second, the tandem repeats project the
CRD toward potential ligands within the ECM. Loss of either or both of these functions, for
the tandem repeats deletion mutant, could be the explanation for both the lower number of
microdomains and their reduced stability. Finally, the importance of carbohydrate
recognition in microdomain stability is also seen by the fact that when DCs are incubated
with 0.2 M lactose, microdomains are seen to become more diffuse and less organized
(Supplemental Figure S4).
Additional significance derives from the fact that apart from cell-cell junctions (27)
including the neuromuscular junction (28) and cell-substratum adhesions (29), where both
extracellular and cytoskeletal factors come into play, there is relatively little precedence for
an important role for extracellular stabilization of membrane domains on free cell surfaces;
indeed, we may expect other examples of this motif to appear in other biological contexts.
A plausible working hypothesis relating microdomain structure to function emerges that is
similar to the SIGLEC hypothesis for lymphoid cells (32, 33): Pathogens with closely
spaced high mannose structures on their surfaces (34) compete with the binding of the CRD
to polysaccharides in the ECM, to activate the receptors and initiate downstream signaling
cascades leading to pathogen internalization. If this hypothesis were correct, it would
suggest that both the mobility of DC-SIGN within microdomains (5–7) and the
nanostructure of the microdomains (4, Itano et al., unpublished) may be altered upon




The construction of pEGFP-C1/DC-SIGN, a plasmid encoding human DC-SIGN in a
modified pEGFP-C1 (Clontech, Palo Alto, CA) vector (in which the EGFP gene was
removed) was described elsewhere (7). The pMX/GFP-DC-SIGN plasmid was kindly
provided by Dr. Dan Littman, New York University and Howard Hughes Medical Institute,
New York, NY. The plasmid was then digested with BamHI and NotI, and GFP-DC-SIGN
fragment was inserted into pEGFP-N1 vector digested with BamHI and NotI, to generate
pEGFP-N1/GFP-DC-SIGN. We previously reported that two cytoplasmic truncations of
DC-SIGN, DC-SIGN-Δ20 and DC-SIGN-Δ35 (in which the first 20 or 35 amino acids from
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the N-terminus were removed) showed no visible effect on membrane microdomain
formation (7). In this study, we further truncated the first 37 aa, i.e. DC-SIGN-Δ37, to
examine whether residue Cys37 is involved in the cell surface microdomain formation. The
following two oligonucleotide primers with an AgeI or NotI site (underlined) were used to
generate the DC-SIGN-Δ37 fragment, using pEGFP-C1/DC-SIGN as the template: 5’-
CCACCGGTCGCCACCATGCTTGGCCATGGTCCCCTGGTG (primer A) and 5’-
TAAAGCGGCCGCTCTACGCAGGAGGGGGGTTTGG (primer B). The resulting PCR
product was digested and inserted into pEGFP-N1 vector (Clontech) by replacing the EGFP
sequence through AgeI and NotI sites. The two N-linked glycosylation site mutation
constructs, i.e. DC-SIGN-N80Q and GFP-DC-SIGN-N80Q, were created using a
QuickChange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA), pEGFP-C1/DC-
SIGN and pEGFP-N1/GFP-DC-SIGN as the templates, respectively, and the following
mutagenic primers (the mutation site is indicated in italics): 5’-
GACGCGATCTACCAGCAGCTGACCCAGCTTAAAG (primer C) and 5’-
CTTTAAGCTGGGTCAGCTGCTGGTAGATCGCGTC (primer D). The two tandem
repeat deletion constructs, DC-SIGN-ΔRepeats and GFP-DC-SIGN-ΔRepeats, were made
by using an overlap extension PCR strategy. To generate DC-SIGN-ΔRepeats, a 0.3 kb
fragment encoding the N-terminal residues 1–80 of DC-SIGN was amplified by PCR with
pEGFP-C1/DC-SIGN as the template and the following two primers: 5’-
CCACCGGTCGCCACCATGAGTGACTCCAAGGAACCA (primer E) and 5’-
CCATTCCCAGGGACAGGGGTGGCAGTTCTGGTAGATCGCGTCTTGCCTG (primer
F), in which Primer E encodes an AgeI site (underlined) and primer F contains the overlap
extension sequence (in italics). A 0.5 kb fragment encoding the C-terminal residues 253–404
of DC-SIGN was amplified by PCR with the following two primers: 5’-
TACCAGAACTGCCACCCCTGTCCCTGGGAATGG (primer G) and primer B, in which
the overlap extension sequence is indicated in italics in primer G, and primer B encodes a
NotI site (underlined). The two PCR products were then purified and mixed as the templates
for the second round overlap extension PCR using primers E and B and the resulting product
was digested and inserted into the pEGFP-N1 vector through the AgeI and NotI sites. GFP-
DC-SIGN-ΔRepeats was generated in a similar manner, using pEGFP-N1/GFP-DC-SIGN
as the template: the first PCR used primer H 5’-
CGGGATCCCGCCACCATGGTGAGCAAGGGC (BamHI site is underlined) and primer F
to generate a 1 kb fragment encoding the EGFP gene and residues 1–80 of DC-SIGN; and
primers G and B were used to generate the 0.5 kb fragment encoding the C-terminal peptide
of DC-SIGN. The 1 kb and 0.5 kb fragments were then mixed as the templates for the
second round overlap extension PCR with primers H and B and the resulting product was
digested and cloned into the pEGFP-N1 vector through BamHI and NotI sites. As most
antibodies against DC-SIGN recognize its CRD, an AU1 tag was introduced at the C-
terminus of the DC-SIGN-ΔCRD construct: 5’-
AAGCGGCCGCTTTATATGTATCTGTAGGTGTCCAGGCGTTCCACTGCAGC (primer
I). Primer I encodes a NotI site (underlined) and the AU1 tag (in italics), and the DC-SIGN-
ΔCRD was generated by PCR using primer E and primer I with pEGFP-C1/DC-SIGN as the
template. The amplified fragment was then digested with AgeI and NotI, and cloned into the
pEGFP-N1 vector, from which the FP gene was removed by digesting with AgeI and NotI.
Similarly, primer H and primer J, 5’-
TTTTGGTTTTGCGGCCGCTTTACAGGCGTTCCACTGCAGC, (NotI site is underlined)
were employed to generate the GFP-DC-SIGN-ΔCRD fragment by PCR with pEGFP-N1/
GFP-DC-SIGN as the template and the resulting product was digested and cloned into
pEGFP-N1 through the BamHI and NotI sites. Construction of GFP-DC-SIGN-Δ37 was
carried out through an overlap extension PCR strategy. The 0.7 kb EGFP gene was
amplified by PCR with pEGFP-N1 (Clontech) as the template and primer H and the
following primer: 5’-
CACCAGGGGACCATGGCCAAGCTTGTACAGCTCGTCCATGCCGAG (primer K).
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Primer H contains a BamHI site and primer K contains the overlap extension sequence (in
italics). The 1.1 kb fragment encoding residues 38–404 of DC-SIGN was amplified by PCR
using pEGFP-C1/DC-SIGN as the template and the following two primers: 5’-
GAGCTGTACAAGCTTGGCCATGGTCCCCTGGTG (primer L) and primer B. Primer L
contains the overlap extension sequence (in italics) and primer B contains a NotI site. The
two PCR products were purified and mixed as templates for the second overlap extension
PCR, using primer H and primer B. The resulting product was digested and inserted into the
pEGFP-N1 vector through the BamHI and NotI sites.
All of the constructs described above were confirmed by DNA sequencing. A schematic
drawing of the constructs is shown in Figure 1 A.
Cell culture and transfection
NIH3T3 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen) supplemented with 10% fetal bovine serum (FBS), 50 U/ml penicillin G and 50
µg/ml streptomycin at 37°C in 5% (v/v) CO2. For observation under the microscope, cells
were seeded in 35 mm glass-bottom MatTek dishes (MatTek Corp., Ashland, MA) at 105
cells/dish one day before transfection. Plasmids were introduced into the cells by following
standard protocols employing either Fugene 6 (Roche, Indianapolis, IN) or Lipofectamine
(Invitrogen) at 2 µg cDNA/dish. After transfection, cells were maintained in normal growth
medium for at least two days either in a 37°C incubator (for the expression of wt DC-SIGN)
or in a 32°C incubator (for the expression of DC-SIGN mutant forms) with 5% CO2.
Incubation at 32°C facilitates protein folding and hence plasma membrane translocation, as
reported previously (11, 35). For immunoblotting of DC-SIGN and mutant proteins, samples
were prepared using a similar procedure as above except that the cells were plated in 60 mm
petri dishes and transfected at 6 µg cDNA/dish.
Immunoblotting
After cultivating the transfected cells for two days, the cells were washed with ice-cold
phosphate buffered saline (PBS) and solubilized with Laemmli sample buffer (200 µl). The
lysates were then heat denatured for 10 min at 95 °C, and stored at −80 °C until use.
Samples were electrophoretically separated with a 4–12% Bis-Tris gel (Invitrogen), and
blotted onto a Hybond-P membrane (Amersham Biosciences, Little Chalfont, UK). After
blocking the membrane with 5% skim milk in Tris Buffered Saline-Tween 20 (TBS-T)
buffer, wt DC-SIGN and the mutant proteins were stained with three types of antibodies:
DCN46 (BD Biosciences, San Jose, CA), for the detection of wt DC-SIGN, GFP-DC-SIGN,
DC-SIGN-Δ37, GFP-DC-SIGN-Δ37, DC-SIGN-N80Q and GFP-DC-SIGN-N80Q; 120507
(R&D Systems, Minneapolis, MN), for the detection of DC-SIGN-ΔRepeats and GFP-DC-
SIGN-ΔRepeats; H-200 (Santa Cruz Biotechnology, Santa Cruz, CA), for the detection of
DC-SIGN-ΔCRD and GFP-DC-SIGN-ΔCRD, respectively. After washing, the membranes
were incubated with either goat anti-mouse AlexaFluor 680-conjugated IgG (Invitrogen; for
DCN46 and 120507 primary Ab) or goat anti-rabbit AlexaFluor 680-conjugated IgG
(Invitrogen; for H-200 primary Ab). The proteins were visualized by scanning the
membranes on an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln,
Nebraska).
Fluorescence labeling
At the time of observation, cells expressing GFP fusions were washed thoroughly with PBS
and then incubated with Hank’s balanced salt solution (HBSS) lacking phenol red during
measurements on the microscope. For cells expressing DC-SIGN and its mutant forms
without the EGFP tag, mAb were employed to stain the receptors on cell surfaces.
Commercially obtained antibodies include the following: mouse monoclonal IgG2b specific
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for human DC-SIGN (DCN46; BD Biosciences); mouse monoclonal IgG2a AU1 antibody
FITC conjugate (FITC-130L; Covance Inc., Princeton, NJ); mouse monoclonal IgG2b
against human DC-SIGN (120507; R&D Systems); AlexaFluor 488-conjugated goat
polyclonal IgG specific for mouse IgG (Invitrogen). For some measurements, the 120507
mAb was directly conjugated to AlexaFluor488, by using a slightly modified procedure to
that based on the kit and the protocol from Invitrogen (mp10235). In our experience, a 5:1
molar ratio of AlexaFluor 488 to antibody usually results in a mean labeling ratio of ~ 1 dye
molecule per IgG. To increase the final dye/antibody ratio, we aimed for a labeling ratio of 3
dyes: 1 IgG. After labeling, the mean dye to IgG ratio was estimated to be 3–7 based on the
corrected absorbance of proteins at 280 nm (major peak of proteins and tails of AlexaFluor
488 spectrum) and at 494 nm (AlexaFluor 488 fluorophores only). The manner in which
these reagents were employed to facilitate confocal imaging and FRAP measurements is
detailed in Supplemental Table S1 (Table S1, Supporting Information).
Microscopy
Cell imaging and FRAP measurements were carried out on an inverted laser scanning
confocal microscope FV1000 (Olympus) with an oil immersion objective (60×, N.A. 1.42;
Olympus) at 37°C. For cell imaging, an excitation wavelength of 488 nm (argon laser) at 6%
power was used and fluorescence emission was collected at 500–540 nm. For each cell
image 1024×1024 pixels were probed at 2 µs/pixel with a pixel size of 69 nm, except that for
the FITC-130L mAb labeled cells the images were collected at 10 µs/pixel due to the
relatively low brightness of fluorescein. For cells expressing the GFP-tagged DC-SIGN and
mutant constructs, some intracellular fluorescence was observed during imaging, likely due
to the ongoing protein synthesis and delivery. To minimize the effect of intracellular
fluorescence in our imaging and domain size analyses, we chose cells in which the majority
of fluorescence was on the membrane, and minimal intracellular fluorescence was observed.
This was achieved in part by imaging cells at later stages after transfection, i.e. 48–72 hours
after transfection, when the majority of the GFP-fusion proteins had been translocated to the
plasma membrane and there was minimal remaining synthesis due to the degradation of the
transiently transfected plasmids. Further, 2D confocal image slices were chosen for analysis
by identifying z-positions where the distribution of fluorescence was either on the dorsal or
ventral cell surfaces (such that no nuclear exclusion of fluorescence was observed), or
confined to the cell periphery (where the fluorescence is visible as punctate outline on the
plasma membrane) (See also Supplemental Figure S5).
For FRAP measurements, a 64×64 pixel (0.11 µm/pixel) area was continuously scanned by
using the 488 nm laser at 6% power for 100–500 frames at 2 µs/pixel rate (except that
FITC-130L labeled cells were imaged at 10 µs/pixel), and photobleaching was carried out
simultaneously at the third frame by using the SIM scanner with the 405 nm diode laser. For
cells expressing GFP fusions or labeled with FITC-130L mAb, the 405 nm laser line was
used at 50% power, and for cells labeled with AlexaFluor 488-conjugated mAb the power
was set at 100% as the Alexa fluorophores are relatively brighter and more stable. For all
sample sets the photobleaching time was 43 ms with the tornado scan feature, and the
effective bleached area ranged from 1.4 to 2 µm in diameter. For the FRAP studies on the
GFP wt DC-SIGN and the GFP mutant forms, the contribution of the GFP fusions in the
internal biosynthetic and endocytotic pathways was minimized by selecting cells in which
the intracellular background was small compared to the fluorescence of the microdomains. It
is possible that the small amount of recovery measured in Figure 3 B, for example, was due
to a small amount of fusion protein in internal membrane compartments where it was
laterally mobile (See also Supplemental Figure S5).
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The size of the microdomains on the cell surface, formed by wt DC-SIGN as well as the
cytoplasmic tail truncation and N-linked glycosylation site mutants, was estimated by
analyzing images from cell samples using an automated program called Localizer (36)
written in Igor Pro (WaveMetrics, Inc., Oregon) software. The fluorescent microdomains on
cell images, called “emitters” in the Localizer program, were segmented by a generalized
likelihood ratio test (GLRT) algorithm (37), which is specifically designed to detect PSF-
shaped (i.e., Gaussian-like) spots. Tentative emission microdomains were passed into
localization routines, in which a symmetric Gaussian was fit to every microdomain using
Levenberg-Marquardt least-squares minimization. Localizations that were too close together
to be independent were discarded. The standard deviation (σ, pixel) was obtained from the
fitting as the width of the “emitter”. The size (diameter, nm) of the microdomains was then
calculated by using the following equation: FWHM = σ pixel × 2.3 × 69 nm/pixel.
The FRAP data analysis has been described previously (7). Briefly, after subtracting
background and correcting for the photobleaching effects during pre-bleach and post-bleach
observation, the % recovery was calculated as: P(t) = 100 × [F(t) − F(0)]/[F(−) − F(0)],
where F(−) is the mean pre-bleach fluorescence intensity and F(0) is the mean fluorescence
intensity right after bleaching. The function P(t) was then fit to an expression, P(t) = P∞ ×
[t/(t+τD)], with P∞ and τD as free parameters, using Igor Pro 6.0 (Wavemetrics, Portland,
OR). From the fit, the values of P∞ were taken as mobile percentages. The values of τD
were used to calculate the diffusion coefficient D using the equation: D = <ω2> /[4 τD],
where ω is the radius of the bleached area.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Construction and expression of DC-SIGN and its mutant forms
A) Schematic overview of DC-SIGN constructs. LL, di-leucine motif; EEE, tri-acidic
cluster; Y, a tyrosine-based activation motif; TM, transmembrane region; CRD,
carbohydrate recognition domain. Solid star (black) denotes Asn80 glycosylation site. Open
star (white) denotes Asn80 changed to a Gln80. B) Detection of DC-SIGN and its mutant
forms by Western blot. Cell lysates from NIH3T3 cells transiently transfected with the
indicated constructs were resolved by SDS-PAGE and subjected to Western blot analysis
using DCN46 mAb (left panel), 120507 mAb (middle panel) and H-200 polyclonal Ab
(right panel), respectively. Lysates from untransfected NIH3T3 cells were used as negative
controls in each panel.
Liu et al. Page 14













Figure 2. Wt DC-SIGN, cytoplasmic truncation and glycosylation site mutation of DC-SIGN
form discrete and stable microdomains on cell surfaces
Confocal images of NIH3T3 cells expressing wt DC-SIGN (A and A’), GFP-DC-SIGN (B
and B’), DC-SIGN-Δ37 (C and C’), GFP-DC-SIGN-Δ37 (D and D’), DC-SIGN-N80Q (E
and E’) and GFP-DC-SIGN-N80Q (F and F’). ‘2D’ represents a single two-dimensional
confocal slice and ‘3D’ represents a three-dimensional maximum intensity projection of
images from confocal z-stacks. Note that for non-GFP tagged constructs, antibody staining
was carried out on non-permeabilized cells so that the staining was confined to the plasma
membrane. Bars, 5 µm.
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Figure 3. DC-SIGN, DC-SIGN-Δ37 and DC-SIGN-N80Q within microdomains do not
appreciably exchange with molecules of the same type in the surrounding environment
(A–F) Normalized fluorescence recovery of a small region containing a bleached
microdomain on NIH3T3 cells expressing wt DC-SIGN (A), GFP-DC-SIGN (B), DC-
SIGN-Δ37 (C), GFP-DC-SIGN-Δ37 (D), DC-SIGN-N80Q (E) and GFP-DC-SIGN-N80Q
(F). Graphs A–C were fit to equation P(t) = P∞ × [t/(t+τD)], while graphs D–F could not be
fit to the equation, so a linear fitting equation, P(t) = a + bt, with a and b as free parameter
constants, was applied instead. The red lines on each graph indicate the results from fitting
to the appropriate equations.
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Figure 4. Size distribution of microdomains formed by DC-SIGN and its mutant forms
(A–F) Microdomain size distribution of wt DC-SIGN (A), GFP-DC-SIGN (B), DC-SIGN-
Δ37 (C), GFP-DC-SIGN-Δ37 (D), DC-SIGN-N80Q (E), and GFP-DC-SIGN-N80Q (F).
(G), Box and whisker plot describing the size distributions for DC-SIGN and mutant
microdomains where the midline within the box represents the median of the distribution,
the top and bottom of the box represents the 75th and 25th percentile of the distribution,
respectively, and the top and bottom tips of the whisker represent the 90th and 10th
percentile, respectively. The size distributions were measured from single confocal image
slices near the ventral surfaces of the cells.
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Figure 5. The tandem repeats deletion mutant of DC-SIGN exhibits both free membrane
diffusion and dynamic microdomains on cell surfaces
(A) Confocal slice of NIH3T3 cells expressing GFP-DC-SIGN-Δrepeats (A-1) or DC-
SIGN-Δrepeats labeled by AlexaFluor 488-conjugated 120507 mAb (A-2); both at lower
expression levels. (B) A sample image, at higher expression levels, of a cell expressing
GFP-DC-SIGN-Δrepeats which exhibits both dynamic microdomains and diffuse membrane
fluorescence. (B-1), Confocal image of a ventral surface section; dynamic microdomains are
indicated by a red arrow and the diffuse membrane fluorescence is indicated by a yellow
arrow. (B-2), maximum intensity projection from confocal z-stacks of another cell. (C) and
(D), Representative FRAP curves measured on the diffusive membrane areas of NIH3T3
cells expressing GFP-DC-SIGN-ΔRepeats (C) or DC-SIGN-ΔRepeats (AlexaFluor 488
conjugated 120507 mAb label) (D), respectively (both at lower expression levels). (E) and
(F), Representative FRAP curves measured on the ‘dynamic microdomain’ areas of NIH3T3
cells expressing GFP-DC-SIGN-ΔRepeats (E) or DC-SIGN-ΔRepeats (AlexaFluor 488
conjugated 120507 mAb label) (F), respectively. Bars, 5 µm.
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Figure 6. Removal of the CRD results in a complete loss of microdomain formation on the cell
surface
(A, from left to right), 2D confocal images of cells expressing GFP-DC-SIGN-ΔCRD (A-1)
and DC-SIGN-ΔCRD labeled by anti-AU1 FITC conjugated mAb (FITC-130L, A-2);
Maximum intensity projections from confocal z-stacks of cells expressing GFP-DC-SIGN-
ΔCRD (A-3) and DC-SIGN-ΔCRD labeled by FITC-130L mAb (A-4); (B–C),
representative FRAP curves on cells expressing GFP-DC-SIGN-ΔCRD (B) and DC-SIGN-
ΔCRD labeled by FITC-130L mAb (C). Bars, 5 µm.
Liu et al. Page 19













Figure 7. Models for DC-SIGN microdomain formation and stability
(A–B) Microdomain formation could be primarily facilitated and stabilized through
interactions between CRDs of DC-SIGN and ECM components. Several possible ways of
linking the CRD to the ECM can be envisioned: first, the CRD binds directly to
glycosaminoglycans and/or proteoglycans or glycosyl moieties of proteins in the ECM (A)
or, second, CRD may bind to transmembrane proteoglycans which could cross-link the
receptor to the ECM as well as to the cytoskeleton (B). On the other hand, glycosylated
transmembrane adaptor proteins (TRAPs) may have cis interactions with DC-SIGN, and
thereby link the receptor to the cytoskeleton, albeit indirectly. Such proteins may serve as
co-receptors with DC-SIGN serving to distinguish different pathogens and to differentiate
downstream signaling pathways. ECM, extracellular matrix. PG, proteoglycan. TRAPs,
transmembrane adaptor proteins.
Liu et al. Page 20
































































































































































































































































































































































































































































Traffic. Author manuscript; available in PMC 2013 May 01.
